SEC EDGARAUG 251 min read$CBLL

Chao Xingjuan sold $146K of CBLL

Chao Xingjuan (President and CEO) sold 6,068 shares of Ceribell, Inc. (CBLL) at $24.02 ($0.15M total) on 2026-08-21.

Original reporting

SEC EDGAR · Chao Xingjuan

Published Aug 25, 2026, 11:20 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 25, 2026, 11:27 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$CBLL

Neutral

high confidence

Mentioned

$CBLL

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CBLLNeutralLow

Why it matters

The transaction is small relative to total holdings and unlikely to affect market perception.

Market read

Routine insider sale with limited trading relevance.

What to watch

Potential upcoming clinical data releases could outweigh the impact of this small insider sale.

Relevance 4/10Novelty 4/10Timing: post‑market filing on Aug 25

Background

Form 4 filings disclose insider transactions; this filing reports a routine sale by Ceribell's CEO.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CBLLNeutralHigh confidence

Context

CEO Chao Xingjuan sold 6,068 shares for $145,753 on Aug 21, lowering his stake to 781,731 shares.

Expected impact

minimal impact; price may stay flat or dip slightly on short‑term selling pressure.

Evidence & confidence

Insider sales under $200k from a CEO are routine and rarely signal material information.

Market effects

Sector

No significant effect on the medical‑device sector.

Regional

Limited to U.S. investors tracking insider activity.

Global

Negligible on a global scale.

Counterpoint

What could challenge this read

If the CEO is reallocating capital, the stock could be undervalued and present a buying opportunity.

Key entities

Company
Ceribell, Inc.
Medical‑device company listed on Nasdaq under CBLL.
Individual
Chao Xingjuan
President and CEO of Ceribell.

Read at source ← All news

OCT 2

$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

rttnews.com3 min

SEP 30

$CBLLMed

Ceribell Gains FDA Clearance For New EEG Monitoring Software

Ceribell, Inc. (CBLL) announced FDA clearance for new EEG monitoring software. The update includes Alpha-Delta Ratio, Relative Alpha, and Burst Suppression monitoring, aiding clinicians in tracking brain activity. The software will be available via update in early 2027. CBLL stock closed at $24.86, up 1.43%.

rttnews.com1 min

SEP 30

$CBLLMedAI 8/10

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

Ceribell, Inc. (Nasdaq: CBLL) received FDA 510(k) clearance for new software for its EEG system, enabling easier interpretation of brain activity trends. The update includes Alpha-Delta Ratio, Burst Suppression, and Amplitude-Integrated EEG monitoring, applicable to patients of all ages. The company expects to roll out the features in the first half of 2027.

globenewswire.com2 min

SEP 17

$BLSMHighAI 8/10

Biotech Stocks At 52-Week Highs - BLSM +18% On Positive Trial Data, ADPT, ILMN, CBLL, NEOG

Biotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.

rttnews.com3 min

AUG 15

$LNTHMed

Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals

Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.

rttnews.com7 min

AUG 10

$CBLLHigh

Ceribell Reports Second Quarter 2026 Financial Results

Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Second Quarter 2026 Financial Results Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor

SEC EDGAR 8-K6 min